Professor Li Wei and her team have been recently awarded a research grant from Cure Parkinson’s Trust to study potential disease-modifying pharmacotherapies for treatment and prevention of Parkinson’s using observational data with a target trial approach framework.
The researchers will examine the effects of istradefylline, montelukast, and ursodeoxycholic acid on progression or prevention of Parkinson’s/early-stage Parkinson’s. The research results will guide and de-risk disease modifying clinical trials that will be conducted within 2-3 years within the EJS ACT-PD platform (
http://ejsactpd.com/).
Professor Li Wei profile